Navigation Links
Drug Cuts Muscle Damage After Heart Attack
Date:2/14/2008

Safety trial shows novel compound blocks enzyme triggering cell and tissue death

THURSDAY, Feb. 14 (HealthDay News) -- A drug designed to lessen muscle damage from a heart attack has passed initial safety tests in humans.

The drug, known as KAI-9803, blocks the activity of an enzyme called delta protein kinase C that triggers cell and tissue death in the aftermath of percutaneous coronary intervention (PCI). PCI is a set of procedures including balloon angioplasty and stent placement that clear and prop open clogged coronary blood vessels that lead to a heart attack.

Although the trial was not designed to demonstrate the efficacy of KAI-9803, researchers said early data suggest it appears to be a promising compound. Results of the study, done at the Duke Clinical Research Institute, are available online and are expected to be published in the Feb. 19 issue of Circulation.

Earlier studies in animals showed that KAI-9803 lessened damage to the heart muscle and quickly restored its pumping function.

"We may not be able to intervene in the first stage of a heart attack, but we think there may be ways to limit damage caused by reperfusion injury," lead investigator Dr. Matthew Roe, a cardiologist at Duke, said in a prepared statement.

The heart suffers damage at two major points in a heart attack, Roe said: first, when a blockage in a coronary artery prevents blood and oxygen from getting to the heart, and then again when the patient undergoes PCI and normal blood flow is restored through reperfusion.

Researchers randomized 154 patients who had suffered heart attacks and were eligible for PCI into either one of four dosing levels of KAI-9803 or a placebo. Patients underwent PCI with physicians injecting the drug directly into their coronary blood vessels during the procedure.

"We designed the trial to find out if KAI-9803 is safe for humans, and we accomplished that goal; we did not see any serious side effects," Roe said. "We also found, however, many promising signs of beneficial drug activity such as lessened damage to the heart muscle and improvement in electrical conductivity in the heart that corresponded to restoration of blood flow to the heart muscle. As a result, we feel this drug has the potential to be helpful in reducing the impact of a heart attack in humans."

More information

To learn more about heart attack warning signs and prevention, visit the National Heart, Lung, and Blood Institute.



-- Kevin McKeever



SOURCE: Duke University Medical Center & Health System, news release, February 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Single Mutation in Mitochondrial DNA Weakens Heart, Muscles
2. Muscle Fatigue Drug May Fight Heart Failure
3. StopMusclePain.com Launched as Only Website Dedicated to Reversing Back Pain
4. Oregon researchers find trigger gene for muscle development
5. Drugs to bulk up muscles may make injuries more likely
6. Embryonic Stem Cells Create Healthy Muscle in Mice
7. New insight into factors that drive muscle-building stem cells
8. Strength training of neck muscles relieves chronic pain
9. Stimulating muscles may improve musicians dystonia
10. SLU researchers show how to stop muscle weakness caused by myasthenia gravis
11. MRE could provide a definitive diagnosis for people with muscle pain, Mayo Clinic study shows
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Cuts Muscle Damage After Heart Attack
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... Offering the ... with an oil many times purer and more potent than the market has seen ... of Gstaad, Switzerland, as well as a patented chromatography process for extraction, to produce ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... in hospitals, today announced it has completed a round of funding to accelerate ... and its partners. Black Granite Capital is a growth equity firm focused on ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... the ATA 2017 President’s Awards recipients, comprised of organizations and individuals who ... , The ATA 2017 President’s Awards recognize individuals and organizations on ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete Miranda, president and CEO ... Enterprising Women magazine as one of its 2017 Enterprising Women of the Year, ... have demonstrated that they have fast-growth businesses, mentor or actively support other women ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... Miami native ... as a dentist. , “I could have never imagined back in 1991 that this ... said Dr. Gallardo. , Over the last 25 years, Dr. Gallardo has pioneered implant ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... DUBLIN , April 20, 2017 Research ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ... to their offering. ... market for drug delivery technologies will rise from USD 20 Billion ... Global Drug Delivery Technologies - Innovation Driven by Rapidly ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ... 99 percent (n=145/146) of chronic hepatitis C virus ... 5 or 6 and compensated cirrhosis (Child-Pugh A) ... (SVR 12 ) with its investigational, pan-genotypic regimen ... rates were seen following 12 weeks of G/P ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
Breaking Medicine Technology: